Ilanit Zada1, Shan Wang1, Meredith Akerman1, Adel Hanna2. 1. Department of Pharmacy, 12297NYU Winthrop Hospital, Mineola, NY, USA. 2. Department of Surgery, 12297NYU Winthrop Hospital, Mineola, NY, USA.
Abstract
BACKGROUND: The prevalence of direct oral anticoagulants (DOACs) has increased with continued evidence of their efficacy and ease of use. However, the rise in their utilization also surfaced a concern regarding their reversal in patients actively bleeding and/or those requiring invasive procedures. Up until 2018, there were several reversal options available including 4-factor prothrombin complex concentrate (4-factor PCC), activated charcoal, desmopressin, and tranexamic acid. Then, in 2018, andexanet alpha, a recombinant factor Xa, was approved for the reversal of apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding. Nonetheless, because 4-factor PCC is more easily attainable and cost-effective, it continues to be the more favorable option for many health-care professionals. METHODS: This retrospective chart review was conducted at NYU Winthrop Hospital in patients who received 4-factor PCC for the reversal of DOACs from January 2018 to July 2018. Patient charts were reviewed and relevant data was collected (admitting diagnosis, dose of 4-factor PCC utilized, etc). RESULTS: Fifty-three patients were evaluated with 85% experiencing a positive response and complete recovery following the administration of 4-factor PCC; 8 (15%) patients died after receiving 4-factor PCC, none as a result of its administration; 3 patients died secondary to other underlying comorbidities, 4 patients died due to an intracranial hemorrhage, and 1 died due to hematoma of the tongue. CONCLUSION: Based on the results thus far, the use of 4-factor PCC may be a good treatment option in patients requiring DOAC reversal.
BACKGROUND: The prevalence of direct oral anticoagulants (DOACs) has increased with continued evidence of their efficacy and ease of use. However, the rise in their utilization also surfaced a concern regarding their reversal in patients actively bleeding and/or those requiring invasive procedures. Up until 2018, there were several reversal options available including 4-factor prothrombin complex concentrate (4-factor PCC), activated charcoal, desmopressin, and tranexamic acid. Then, in 2018, andexanet alpha, a recombinant factor Xa, was approved for the reversal of apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding. Nonetheless, because 4-factor PCC is more easily attainable and cost-effective, it continues to be the more favorable option for many health-care professionals. METHODS: This retrospective chart review was conducted at NYU Winthrop Hospital in patients who received 4-factor PCC for the reversal of DOACs from January 2018 to July 2018. Patient charts were reviewed and relevant data was collected (admitting diagnosis, dose of 4-factor PCC utilized, etc). RESULTS: Fifty-three patients were evaluated with 85% experiencing a positive response and complete recovery following the administration of 4-factor PCC; 8 (15%) patients died after receiving 4-factor PCC, none as a result of its administration; 3 patients died secondary to other underlying comorbidities, 4 patients died due to an intracranial hemorrhage, and 1 died due to hematoma of the tongue. CONCLUSION: Based on the results thus far, the use of 4-factor PCC may be a good treatment option in patients requiring DOAC reversal.
Entities:
Keywords:
4-factor PCC; Direct Oral Anticoagulants (DOACs); hematoma; intracranial hemorrhage
Authors: C Beynon; M Bernhard; T Brenner; M Dietrich; M O Fiedler; C Nusshag; M A Weigand; C J Reuß; D Michalski; C Jungk Journal: Anaesthesist Date: 2021-01 Impact factor: 1.041
Authors: Carlin C Chuck; Daniel Kim; Roshini Kalagara; Nathaniel Rex; Tracy E Madsen; Leana Mahmoud; Bradford B Thompson; Richard N Jones; Karen L Furie; Michael E Reznik Journal: Neurology Date: 2021-09-23 Impact factor: 11.800
Authors: Victoria M Stevens; Toby C Trujillo; Tyree H Kiser; Robert MacLaren; Paul M Reynolds; Scott W Mueller Journal: Clin Appl Thromb Hemost Date: 2021 Jan-Dec Impact factor: 2.389
Authors: Charlie J Nederpelt; Leon Naar; Katelyn W Sylvester; Megan E Barra; Russel J Roberts; George C Velmahos; Haytham M A Kaafarani; Martin G Rosenthal; David R King Journal: J Thromb Haemost Date: 2020-08-27 Impact factor: 5.824